Ultragenyx reports preliminary 2025 revenue of $672-674 million
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/10/2026
- Wall Street indexes fall more than 1%, hit by tech, Iran war worries
- Oracle results beat estimates, but shares fall on plans for $40 billion raise
- Oil prices jump after Trump threatens to hit Iran 'very hard'
- Oracle reports earnings today: Analysts say this metric could 'catalyze higher multiples'
- UBS sees generational semiconductor boom, highlights stock winners
- Hut 8 Mining Corp. (HUT) PT Raised to $55 at KBW As Management Delivers
- Needham Starts Hyliion Holdings (HYLN) at Buy
- Micron to deliver 'another strong quarter', Goldman says
- Supermicro plans $7 billion financing to fund AI server orders
- UK's Ofcom requires tech firms to create crisis response plans
Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference
January 12, 2026 7:30 AM ESTPreliminary 2025 total revenue of $672 million to $674 million, exceeding top end of guidanceÂ
Preliminary cash and investments of approximately $735 million as of December 31, 2025
Anticipated 2026 catalysts include two potential approvals and pivotal Phase 3 data from the GTX-102 Phase 3 Aspire study for Angelman syndrome
NOVATO, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today reported preliminary unaudited 2025 revenue results, cash and investments at year end 2025, and provided a... More
